In May, the FDA approved atezolizumab in combination with bevacizumab for newly diagnosed patients with hepatocellular carcinoma.
A case report about a novel two-pronged treatment for a patient with a large hepatocellular carcinoma/cholangiocarcinoma shows the value of multidisciplinary collaboration, especially among experts in interventional radiology and radiation oncology.
Statin use substantially reduces the risk of hepatocellular carcinoma and should be considered as a standard of care in patients at high risk for the disease, according to a Cleveland Clinic meta-analysis.
Patients with inflammatory conditions and concomitant cirrhosis who are treated with tumor necrosis factor inhibitors face heightened risk of serious infections and other complications, according to new Cleveland Clinic research.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Study reveals that the successful downstaging of advanced HCC via locoregional therapy prior to transplant yields 5-year survival rate of 60 percent. Two liver experts explain the impact on patients and the transplant community.
HALT-HCC is practical, easy to implement and outperformed other selection criteria. It has the potential to become a new clinical tool that can lead to more efficient use of donated organs.
Denied surgery elsewhere, a 77-year-old undergoes a complex liver resection for hepatocellular carcinoma with outstanding results.